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Background: Heart-type fatty acid-binding protein (H-FABP) is a heart-specific and highly sensitive biomarker
for early diagnosis of acute myocardial infarction (AMI). We investigated the effectiveness of H-FABP for
diagnosis of AMI in patients with different ethnic background and different time from symptom onset.
Methods: Venous blood was withdrawn from consecutive patients with acute chest pain admitted to the
First Affiliated Hospital of Xinjiang Medical University. The blood samples were used for measurement of
creatine kinase MB (CK-MB) and cardiac troponin I (cTnI) using Beckman Coulter DC-800 analyzer, and
detection of H-FABP using a one-step bedside immunotest.
Results: Two hundred and eighty-nine patients admitted within 12 h after the onset of symptoms were
recruited in the study. The H-FABP immunotest was found to have higher diagnostic accuracy than cTnI and
CK-MB in patients admitted within 3 h. The combination of H-FABP and cTnI was found to have the highest
diagnostic accuracy (91%) among different cardiac markers and the other combinations. It gave the highest
sensitivity [96% (95% CI: 91–98%)] and a comparable specificity [84% (95% CI: 76–89%)] to cTnI alone.
Conclusion: A cardiac panel consisting of H-FABP and troponin is recommended.
© 2010 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease causes a major burden in health care and is
the single most costly disease for the health care system. It has been
increasing in the past few decades in China, the largest and most
populous developing country in the world. Acute myocardial infarction
(AMI) is the leading cause of mortality among cardiovascular disease.
The high mortality rate can be dramatically reduced by early diagnosis
and effective coronary reperfusion.
From the ED perspective, it is important to expeditiously distinguish
betweenAMI and non-AMI patients so as to be able to immediately startlogy; AMI, acute myocardial
ciety of Cardiology; H-FABP,
anges; LR-, negative likelihood
PV, negative predictive value;
anization.
The Hong Kong University of
ong Kong. Renneberg is to be
4. Chan, Tel.: +852 2358 0220;
neb@ust.hk (R. Renneberg).
l rights reserved.proper treatment. Although electrocardiogram (ECG) is a standard test
to identify patients with AMI upon ED presentation, it still has relatively
low sensitivity for detection of AMI (only 35–50%) [1]. Instead, plasma
markers of myocardial injury ultimately show almost 100% sensitivity,
dependent on the delay in their release into plasma.
Recently, a one-step bedside H-FABP immunotest so-called Cardio-
Detect® designed to detect H-FABP in whole blood samples has become
commercially available [2–6]. The test result is available within 15 min
after addition of blood samples. It requires no sample pretreatment and,
therefore, is suitable especially for application in an emergency situation.
Many studies in the developed countries like Europe and Japan have
demonstrated the superior performance of H-FABP for diagnosis of AMI
in the early stage [7–12]. However, such information is still relatively
insufficient in the developing countries with inconvenient traffic, low
educational level, lackof hospital resources andcomprehensive facilities.
Study about the utility of H-FABP for diagnosis of AMI in China is also
limited.
The prevalence of several chronic diseases in Xinjiang including
myocardial infarction, diabetes, hypertension, and cancers is difference
among different ethnic groups. Therefore, the present study aimed at
investigating the effectiveness of the H-FABP immunotest compared to
1782 Q. Xu et al. / Clinica Chimica Acta 411 (2010) 1781–1787current cardiac markers for diagnosis of AMI in patients with different
ethnic background, different chronic diseases, different genders and
different time from symptom onset in Xinjiang. Also, the diagnostic
performance of different combinations of cardiac markers was
compared. This study may act as a reference for those developing
countries and the results can be compared to those studies conducted in
developed countries to assess the universal applicability of the H-FABP
immunotest for diagnosis of AMI. This study has been divided into two
phases: Phase I has been implementing in Urumqi for 3 y; Phase II will
be implemented in the southern, northern and eastern parts of Xinjiang
for 4 y.2. Methods
2.1. Study design and setting
According to the Declaration of Helsinki, the design of this study
was to investigate the diagnostic accuracy of the H-FABP immunotest.
This study was reviewed and approved by the ethical committee of
the First Affiliated Hospital of Xinjiang Medical University in
November 2007 with document number: No. 20071108. The First
Affiliated Hospital of XinjiangMedical University is a teaching hospital
in the western border of area of Urumqi in Xinjiang. In 2007, there
were 2332 visits for cardiovascular diseases to the Emergency
Department (ED) of this hospital; 502 of them suffered from chest
pain and 158 of these patients ultimately have been diagnosed as
acute myocardial infarction (AMI) and 57 as angina pectoris.
This was a double-blind parallel study. Consecutive patients with
acute chest pain admitted to the ED of the First Affiliated Hospital of
XinjiangMedical University were diagnosed according to the ESC/ACC
guideline and the H-FABP immunotest. Fig. 1 showed the diagnostic
pathway in this study.
A comprehensive study design and accurate data collection were
relied on a well-organized preliminary study. The preliminary study
was implemented from September 2007 to November 2007 and 40
consecutive patients were recruited. The study protocol were revised
and finalized after the preliminary study. All the patients in the
preliminary study were not included in the current study.Fig. 1. Diagnostic pathway of the study.2.2. Inclusion and exclusion criteria
Patients were included in this study if (i) they aged≥18 y, (ii) chest
pain suggestive of coronary origin at the discretion of an ED physician's
assessment, (iii) and onset of chest pain b12 h prior to enrollment.
Patients were excluded if (i) they were unable to give consent or
unwilling to join the study; (ii) they had chronic renal injury (creatinine
in serumN100 mol/l orN1.5 mg/dl); (iii) theyhad intentionneuralgia or
recent pain related to thoracic trauma within 3 days; (iv) they had
severe skeletal muscle injury.
2.3. Patient assessments and investigations
According to the ESC/ACC guideline [13,14], patients were
confirmed as AMI patients if they had (i) typical acute chest pain;
(ii) abnormal 12-lead ECG defined as pathologic Q waves of N40 ms,
ST-segment elevation or depression of N1 mm or abnormal T wave
morphology; (iii) the cTnI concentration above the 99th percentile
cutoff with a CV b10%.
The onset time of symptoms was critical in this study. The time
was based on the subjective reports of the patients about the onset of
chest pain. In order to minimize the variation, the medical doctors
asked the patients and their relatives twice respectively. The ECG was
examined by 2 internal medicine specialists and the final result was
reported by the Vice Director at the ED.
2.4. Laboratory analysis
Venous blood was withdrawn from patients suspected of AMI at
admission. The blood samples were used for detection of CK-MB, cTnI
and H-FABP. The concentrations of CK-MB and cTnI were determined
by using Beckman Coulter DC-800 chemistry analyzer. The cut-off
values for CK-MB and cTnI were set at 25 U/l and 0.03 μg/l respective-
ly. The final report was approved by a senior medical doctor in the
Department of Laboratory Medicine. The measurement of all the
cardiac markers using the analyzer in each sample was completed
within 30–50 min. The final diagnosis was made by the Director at
CCU and the Director at ED who were blinded to the H-FABP results.
All patients were also tested with CardioDetect® H-FABP immunot-
est (Fig. 2). It is a rapid chromatographic immunoassay designed forFig. 2. CardioDetect®: a chromatographic immunotest for qualitative detection of H-FABP.
The test result was positive if two red lines were visible (left). The result was negative if
only one red linewas visible at the control zone (middle). The testwas invalid if no control
line was visible (right).
1783Q. Xu et al. / Clinica Chimica Acta 411 (2010) 1781–1787qualitative determination of H-FABP in blood samples with a cut-off
value of 7 μg/l. The working principle of the H-FABP immunotest was
based on a sandwich immunoassay using a pair of monoclonal
antibodies with the detector labeled with colloidal gold. The test
required 100–120 μl of sample and the result was interpreted within
15 min after sample application. The test result was positive if two red
lineswere visible (one at the area of the test zone and one at the control
zone). This indicated that the concentration of H-FABP in the sample
was above the threshold value of 7 μg/l and that an AMI had occurred.
The result was negative if only 1 red linewas visible at the control zone.
This reading indicated that the concentration of H-FABP in the sample
was below the threshold value and that an AMI had not occurred. The
testwas invalid if no linewas visible or if a line only at the test zonewas
visible. In such a case, the measurement was repeated immediately.
The result of the H-FABP immunotest was judged by two
independent master students at CCU. They had no information about
the final diagnosis. The results and the final diagnosiswere summarized
in a cross table for analysis by a doctoral studentwhodid not participate
in any measurement. The study database was setup and organized by
two statisticians by using double data entry and double checking
method to ensure data accuracy.2.5. Clinical trial registration
The World Health Organization (WHO) officially announced the
expansion of its clinical trial registry platform to include trial registers
from China in July 2007. This study was registered under the Chinese
Clinical Trial Register (http://www.ctrni.org) in November 2007. The
clinical trial registration number was ChiCTR-DT-00000040.2.6. Statistical analysis
Data are presented as medians and interquartile ranges (IQR).
Sensitivities with 95% confidence intervals (95% CI), specificities with
95% CI, negative and positive predictive values (NPV and PPV),
negative and positive likelihood ratios (LR- and LR+) of each cardiac
marker and different combinations in 2 groups with different onset of
symptoms (0–6 vs. 6–12 h) and in different ethnic groups were
calculated by using SPSS13.0 (Chicago, IL) and MedCalc ver 7.0
(MedCalc Software, Mariakerke, Belgium). Diagnostic accuracy was
defined as a proportion of correctly classified subjects (TP+TN)
among all subjects (TP+TN+FP+FN). The level of significance was
set at pb0.05 (Table 1).Table 1
Demographic characteristics and risk factors of study subjects.
n AMI Non-AMI
Age, year [M(P25, P75)] 61 (50, 69) 61 (50, 70) 60 (46, 69)
Sex (%) 274 157 (57 ) 117
Male 196 121 (62%) 75
Female 78 36 (46%) 42
Ethnic group (%)
Han 180 98 (54%) 82
Uygur 66 43 (65%) 23
Hui 17 9 (53%) 8
Kazakh 9 5 (56%) 4
Xibe 2 2 (100%) 0
Risk factors (%)
Diabetes 63 30 (48%) 33
Hypertension 133 51 (38%) 82
History of ischemic heart disease 109 37 (34%) 72
History of smoking 165 91 (55%) 74
History of cerebrovascular disease 26 12 (46%) 143. Results
Between 19 November 2007 and 15 February 2009, 289 patients
were recruited to the study (Fig. 3). Three patients without consent
and 12 patients' diagnosis not based on the ESC/ACC guideline were
excluded. Therefore, 15 patients were excluded leaving 274 patients
(median age: 61 y; IQR: 50–70 y; 28.5% female) for analysis. Among
the 274 patients, there were 180 Han patients (65.8%), 66 Uygur
patients (24%), 17 Hui patients (6.2%), 9 Kazak patients (3.3%) and 2
Xibo patients (0.7%). Themedian time from symptom onset to the first
blood sample was 5 h (IQR: 3–6 h).3.1. Diagnostic performance of H-FABP immunotest
The diagnostic performance of different cardiac markers and
the combinations in patients suspected of AMI admitted to the
hospital within 12 h after the onset of symptoms is summarized in
Table 2. The sensitivity and specificity of the H-FABP immunotest
were 87% (95% CI: 81–92%) and 84% (95% CI: 76–89%) respectively.
The PPV and NPV were 88% and 83% respectively. The LR+ and LR–
were 5.37 and 0.15 respectively. The false negative ratio was 13% while
the false positive ratio was 16%. There were 19 patients with false
positive results including 4 patients with cerebrovascular accident, 4
unstable angina patients, 3 patients with old myocardial infarction, 2
patientswith cardiac arrhythmia, 2 patientswith essential hypertension
(grade III), 1 patient with pulmonary embolism, 1 patient with acute
pancreatitis, 1 patient with left ventricular failure and 1 patient with
stable angina.
The H-FABP immunotest was found to have higher sensitivity and
NPV than CK-MB while its specificity and PPV were comparable to
both cTnI and CK-MB. At the time of ED presentation, the use of both
early and late markers rather than the gold standard troponins alone
increases the diagnostic performance. The combination of H-FABP and
cTnI was found to have the best diagnostic performance among
different cardiac markers and the other combinations. It gave the
highest sensitivity and NPV while its specificity and PPV were
comparable to cTnI alone (Table 2).3.2. Diagnostic performance of different cardiac markers in patients with
different time from symptom onset
The sensitivity and specificity of H-FABPwere 79% (95% CI: 65%–89%)
and 80% (95% CI: 65%–89%) respectively for patients admitted 0–3 h after
the onset of symptoms, while the sensitivity and specificity of H-FABP
increased to 93% (95% CI: 83%–97%) and 90% (95% CI: 77%–96%)
respectively for patients admitted 6–12 h after the onset of symptoms
(Table 2).
Among patients admitted 0–3 h after the onset, the H-FABP
immunotest was found to have higher sensitivity and specificity than
both cTnI and CK-MB. The combination of H-FABP and cTnIwas found
to have the highest diagnostic accuracy (85%) among different
cardiac markers and the other combinations in the early phase of
AMI.
Among patients admitted 6–12 h after the onset, both the sensitivities
and specificities of all single cardiac markers increased to 90% or above
whileonly the sensitivityofCK-MBwas slightlybelow90%. Thediagnostic
performance of cTnI and the combination of cTnI and CK-MBwas the best
among different cardiac markers and the other combinations in the late
phase of AMI.
Among patients admitted 0–12 h after the onset, the combination
of H-FABP and cTnI was found to have the highest diagnostic accuracy
(91%) among different cardiac markers and the other combinations. It
gave the highest sensitivity [96% (95% CI: 91–98%)] and a comparable
specificity [84% (95% CI: 76–89%)] to cTnI alone.
Fig. 3. Flow chat of study population.
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groups
The sensitivity and specificity of H-FABP in the Han patients
were 87% (95% CI: 81%–92%) and 85% (95% CI: 76%–91%), while
the sensitivity and specificity of H-FABP in the Uygur patients were
88% (95% CI: 76%–95%) and 78% (95% CI: 58%–90%) (Table 3). There
was no statistically significant difference in the diagnostic perfor-Table 2
Diagnostic performance of H-FABP immunotest, cTnI and CK-MB for diagnosis of AMI.
Onset time n TP FP FN TN Diagn
accur
0–3 h H-FABP 87 34 9 9 35 0.79
cTnI 87 33 10 10 34 0.77
CK-MB 87 27 10 16 34 0.70
H-FABP+cTnI 87 40 10 3 34 0.85
H-FABP+CK-MB 87 35 13 8 31 0.76
cTnI+CK-MB 87 34 14 9 30 0.74
H-FABP+cTnI+CK-MB 87 40 14 3 30 0.80
3–6 h H-FABP 92 52 6 7 27 0.86
cTnI 92 55 2 4 31 0.93
CK-MB 92 34 2 25 31 0.71
H-FABP+cTnI 92 58 5 1 28 0.93
H-FABP+CK-MB 92 51 5 8 28 0.86
cTnI+CK-MB 92 54 4 5 29 0.90
H-FABP+cTnI+CK-MB 92 58 4 1 29 0.95
6–12 h H-FABP 95 51 4 4 36 0.92
cTnI 95 52 1 3 39 0.96
CK-MB 95 49 3 6 37 0.91
H-FABP+cTnI 95 52 4 3 36 0.93
H-FABP+CK-MB 95 51 7 4 33 0.88
cTnI+CK-MB 95 52 1 3 39 0.96
H-FABP+cTnI+CK-MB 95 52 7 3 33 0.89
Overall H-FABP 274 137 19 20 98 0.86
cTnI 274 140 13 17 104 0.89
CK-MB 274 110 15 47 102 0.77
H-FABP+cTnI 274 150 19 7 98 0.91
H-FABP+CK-MB 274 137 25 20 92 0.84
cTnI+CK-MB 274 140 22 17 95 0.86
H-FABP+cTnI+CK-MB 274 150 25 7 92 0.88
TP: true positive; FP: false positive; FN: false negative; TN: true negative; Sen: sensitivity; Spe
predictive value: PV–: negative predictive value.mance of the H-FABP immunotest among the Han and Uygur patients
(pN0.05).
3.4. Diagnostic performance of H-FABP immunotest in patients of different
genders
The sensitivity and specificity of H-FABP in males were 90% (95% CI:
83%–94%) and 86% (95% CI: 77%–92%) respectively, while the sensitivityostic
acy
Sen 95%CI Spe 95%CI LR+ LR- PV+ PV-
0.79 (0.65–0.89) 0.80 (0.65–0.89) 3.87 0.26 0.79 0.80
0.77 (0.62–0.87) 0.77 (0.63–0.87) 3.38 0.3 0.77 0.77
0.63 (0.48–0.76) 0.77 (0.63–0.87) 2.76 0.48 0.73 0.68
0.93 (0.81–0.98) 0.77 (0.63–0.87) 4.09 0.09 0.80 0.92
0.81 (0.67–0.90) 0.70 (0.56–0.82) 2.75 0.26 0.74 0.79
0.79 (0.65–0.89) 0.68 (0.53–0.80) 2.49 0.31 0.71 0.77
0.93 (0.81–0.98) 0.68 (0.53–0.80) 2.92 0.10 0.74 0.91
0.88 (0.77–0.94) 0.82 (0.66–0.91) 4.85 0.15 0.90 0.79
0.93 (0.84–0.97) 0.94 (0.80–0.98) 15.38 0.07 0.96 0.89
0.58 (0.45–0.69) 0.94 (0.80–0.98) 9.51 0.45 0.94 0.55
0.98 (0.91–1.00) 0.85 (0.69–0.93) 6.49 0.02 0.92 0.97
0.86 (0.75–0.93) 0.85 (0.69–0.93) 5.71 0.16 0.91 0.78
0.92 (0.82–0.96) 0.88 (0.73–0.95) 7.55 0.10 0.93 0.85
0.98 (0.91–1.00) 0.88 (0.73–0.95) 8.11 0.02 0.94 0.97
0.93 (0.83–0.97) 0.90 (0.77–0.96) 9.27 0.08 0.93 0.90
0.95 (0.85–0.98) 0.98 (0.87–1.00) 37.82 0.06 0.98 0.93
0.89 (0.78–0.95) 0.93 (0.80–0.97) 11.88 0.12 0.94 0.86
0.95 (0.85–0.98) 0.90 (0.77–0.96) 9.45 0.06 0.93 0.92
0.93 (0.83–0.97) 0.83 (0.68–0.91) 5.30 0.09 0.88 0.89
0.95 (0.85–0.98) 0.98 (0.87–1.00) 37.82 0.06 0.98 0.93
0.95 (0.85–0.98) 0.83 (0.68–0.91) 5.40 0.07 0.88 0.92
0.87 (0.81–0.92) 0.84 (0.76–0.89) 5.37 0.15 0.88 0.83
0.89 (0.83–0.93) 0.89 (0.82–0.93) 8.03 0.12 0.92 0.86
0.70 (0.62–0.77) 0.87 (0.80–0.92) 5.46 0.34 0.88 0.68
0.96 (0.91–0.98) 0.84 (0.76–0.89) 5.88 0.05 0.89 0.93
0.87 (0.81–0.92) 0.79 (0.70–0.85) 4.08 0.16 0.85 0.82
0.89 (0.83–0.93) 0.81 (0.73–0.87) 4.74 0.13 0.86 0.85
0.96 (0.91–0.98) 0.79 (0.70–0.85) 4.47 0.06 0.86 0.93
: specificity; LR+: positive likelihood ratio; LR–: negative likelihood ratio; PV+: positive
Table 3
Diagnostic performance of H-FABP immunotest in patients with different ethnics, genders and chronic diseases.
n TP FP FN TN Diagnostic
accuracy
Sen (95%CI Spe (95%CI) LR+ LR- PV+ PV-
Ethnic group
Han 180 85 12 13 70 0.86 0.87 (0.79–0.92) 0.85 (0.76–0.91) 5.80 0.15 0.88 0.84
Uygur 66 38 5 5 18 0.85 0.88 (0.76–0.95) 0.78 (0.58–0.90) 4.00 0.15 0.88 0.78
Hui 17 8 1 1 7 – – – – – – –
Kazakh 9 5 1 0 3 – – – – – – –
Xibe 2 1 0 1 0 – – – – – – –
Gender
Male 196 105 11 12 68 0.88 0.90 (0.83–0.94) 0.86 (0.77–0.92) 6.54 0.12 0.91 0.85
Female 78 32 8 8 30 0.79 0.80 (0.65–0.90) 0.79 (0.64–0.89) 3.80 0.25 0.80 0.79
Chronic disease
Diabetes and hypertension 19 11 3 2 3 0.74 0.85 (0.58–0.96) 0.50 (0.19–0.81) 9.13 0.17 0.79 0.60
Diabetes only 63 28 6 6 23 0.81 0.82 (0.66–0.92) 0.79 (0.62–0.90) 3.98 0.22 0.82 0.79
Hypertension only 133 47 7 9 70 0.88 0.84 (0.72–0.91) 0.91 (0.82–0.96) 9.23 0.18 0.87 0.89
No diabetes and hypertension 59 51 3 3 2 0.90 0.94 (0.85–0.98) 0.40 (0.12–0.77) 1.57 0.14 0.94 0.40
Note: as the number of cases of Hui, Kazakh and Xibe groups were small, the diagnostic accuracy, Sen, Spe, PV+, PV–, LR+, LR– were not calculated.
TP: true positive; FP: false positive; FN: false negative; TN: true negative; Sen: sensitivity; Spe: specificity; LR+: positive likelihood ratio; LR–: negative likelihood ratio; PV+:
positive predictive value: PV–: negative predictive value.
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and 79% (95% CI: 64%–92%) respectively (Table 3). There was no
statistically significant difference in the diagnostic performance of
the H-FABP immunotest among males and females (pN0.05). The
diagnostic performance of H-FABP was higher in males than in
females.
3.5. Diagnostic performance of H-FABP immunotest in patients with
different chronic diseases
The diagnostic performances of H-FABP in patients with and
without diabetes and hypertension were shown in Table 3. Patients
without both diabetes and hypertension gave the highest sensitivity
[94% (95% CI: 85%–98%)] but the lowest specificity [40% (95% CI: 12%–
77%)]. Patients with only hypertension gave the optimal sensitivity
[84% (95% CI: 72%–91%)] and specificity [91% (95% CI: 82%–96%)].
4. Discussion
4.1. Diagnostic performance of H-FABP immunotest
The appropriate handling of patients with suspected AMI depends
on the availability of results from simple, sensitive and specific
diagnostic tests. In patients with typical early ECG changes of ST-
segment elevation, thediagnosis of AMI is easily and rapidly established.
However, at least 40% of patients with AMI show no diagnostic ECG
changes on admission. Also, in approximately 60 to 70% of patients
admitted to hospital because of chest pain, the suspicion of AMI will
ultimately be dismissed because of lack of diagnostic ECG changes and
negative biochemical tests. In the past, early diagnosis of AMI mainly
depended on the detection ofmyocardial injurymarkers such as cardiac
troponins, creatine kinase (CK) or its isoenzyme (CK-MB), and
myoglobin (MYO). Heart-type fatty acid binding protein (H-FABP) has
been suggested as an early cardiacmarker for diagnosis of AMI [15–21].
It is a small cytosolic protein and is abundant in cardiac tissue. It is
responsible for the intracellular transport of the insoluble fatty acids
within the cells. Its concentration in the plasma of healthy persons is
relatively low at 0.3–6 μg/l [15,22]. After myocardial ischemic damage,
H-FABP can be detected in the blood as early as within 1 h after onset of
chest pain, with peak values reached at 3–6 h and plasma levels
returning to normal within 24–30 h [16,22]. The combination of initial
H-FABP release after symptom onset, rapid kidney clearance from the
circulation and high cardiac specificity makes it as an early cardiac
marker for diagnosis of AMI and reinfarction.This study has demonstrated that the H-FABP immunotest gave
higher sensitivity and specificity than cTnI and CK-MB in patients
admitted to the hospital within 3 h after the onset of symptoms. The
small molecular weight of H-FABP (15 kDa) favors its early release,
due to the higher permeability of the endothelial barrier for small
proteins. Also, the amount of H-FABP in myocardium is 10-fold higher
than that in skeletal muscle. These characteristics, along with a low
physiological concentration for the identification of myocardial
damage, enable H-FABP to have an improved diagnostic capability
[23,24]. The use of the H-FABP immunotest appears to be of unique
value in the early stage of AMI. Chan et al. demonstrated that H-FABP
reliably diagnosed AMI patients 1 h after admission and 100% of non-
AMI patients were excluded with no false negative results [16]. The
late markers cTnI and creatine kinase (CK) have the similar diagnostic
performance only 7 h later.
Most of previous studies have reported that H-FABP gave signifi-
cantly higher sensitivity and better diagnostic performance than cTnI
especially at the early phase ofAMI [5,6,12,25,26]. In this study,we found
that the sensitivities of H-FABP and cTnI were comparable. This may be
explained by the utilization of different cutoff values for cTnI in various
studies. In this study, the cutoff value for cTnI was 0.03 μg/l which
corresponded to the 99th percentile cutoff with a CV b10%. This cutoff
valuewas lower than thoseused inmost of previous studies for diagnosis
of AMI (0.05–1.5 μg/l) and thus enhanced its sensitivity.
Xinjiang is a multi-ethnic region. This study only included patients
from Han, Uygur, Hui, Kazakh and Xibe, which occupy 98.2% of the
population in Xinjiang. The Uygur and Han patients were dominated
in this study as the Uygurs is the largest ethnic group (45%) and the
Han is the second (41%). In this study, we found that there was no
statistically significant difference in the diagnostic performance of the
H-FABP immunotest among the Han and Uygur patients.
The prevalence rate of AMI case in the recruited cases not only
depends on the inclusion and exclusion criteria, but also depends on
recruiting site. In this study, the prevalence rate of AMI case recruited
at the ED was 57% which was similar to the studies reported by
Alhashemi et al. (64.1%) [5] and Ecollan et al. (50.9%) [6].
This study also demonstrated that there was no statistically
significant difference in the diagnostic performance of the H-FABP
immunotest among males and females. On the other hand, patients
without both diabetes and hypertension gave the highest sensitivity
but the lowest specificity. The low specificity could be explained by the
small number of non-AMI cases in this group. Therefore, the diagnostic
performance of H-FABP immunotest in patients with different chronic
diseases should be further investigated.
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No single cardiac marker used alone is ideal. Although troponins
are the gold standard cardiac markers, they still fail in two important
aspects: the ability to detect early AMI and reinfarction. In view of the
poor troponin sensitivity in the early detection of myocardial injury
within the first 6 h after the onset of symptoms, a cardiac multi-
marker strategy is of particular value when the analytical sensitivity
of the troponin detection method is unsatisfied. A panel consisting of
H-FABP and troponin is recommended rather than troponin in
combination with myoglobin [27]. Patients presenting very early
(b2 to 3 h after symptom onset) may have elevations in H-FABP in
the absence of cTnI increase. When cTnI is elevated in the absence of an
H-FABP elevation, it is usually a delayed presentation. Most typically,
discordant results are helpful to the clinician because they can identify a
high-risk patient who may be missed if only one marker is tested.
The current study shows that a combination ofH-FABP and cTnI tests
gave the highest sensitivity and NPV while showed the specificity and
PPV comparable to the cTnI test alone. This combination enhanced the
sensitivity and NPV without sacrificing the specificity and PPV. The
highest sensitivity andNPVof this combinationplayan important role in
minimizing the number of false negative result and thus allowing safely
exclusion of non-AMI patients at an early stage. It also gave the highest
diagnostic accuracy and thus was the most effective diagnostic tool for
diagnosis of AMI. Mion et al. [28] also demonstrated that the
combination of cTnI and H-FABP gave the greatest diagnostic efficacy
in AMI diagnosis in northern Italy. A rapid bedside immunotest allows
H-FABP to be used in clinical settings, together with other clinical tools
such as troponin test, to diagnose and treat cardiac patients as soon as
possible so thatmortality andmorbidity can be decreased. This strategy
may allow the complete detection of cardiac injury and may improve
the diagnosis of AMI on the initial sample. Further investigation should
be conducted to confirm the efficiency of this strategy.
4.3. Limitations of the study
This study was limited by the number of patients and a continuous
measurement of H-FABP was omitted after confirmation as a negative
case. Chan et al proved that the sensitivity and the negative predictive
value of H-FABP reached to 100% in 1 h after admission [16]. Whether
the re-measurement of H-FABP negative samples after 1 h can
improve the diagnostic accuracy should be further investigated.
4.4. Impact on clinical practice
As the therapeutic window for AMI is within the first 6 h, and an
earlier intervention has a better success rate, the availability of an
early rapid test is important. In order to decrease the risk of falsely
excluded patientswith ongoing AMI, a combinedmeasurement of two
cardiac markers, an early one such as H-FABP and a later marker such
as troponins may provide the optimum diagnostic performance.
In this study, a 1-step H-FABP immunotest based on a sandwich
principle was evaluated. Apart from its high diagnostic accuracy the
H-FABP immunotest is very easy to be operated and thus favorable to
be used in ambulance, emergency department and any emergency
situation. Its simplicity in operation makes it a user-friendly test for
application by chronic patients with high risk in AMI at home.
Recent studies about the application of the H-FABP immunotest for
diagnosis of AMIweremainly reported in somedeveloped countries like
Europe and Japan [7–12]. Due to unfair distribution ofmedical resources
across theworld, theneedof theH-FABP immunotest is always higher in
the developing countries than the developed countries, especially for
hospitals located at the countryside. The Xinjiang Uygur Autonomous
Region is located in the North West corner of China. Its characteristics
like low population density, poor transportation system, relatively poor
economic and educational development, and lack of infrastructureimprovements to promote hygiene reflects the key characteristics of the
developing countries, and thus there is an urgent need to have a rapid
system for early diagnosis of AMI.
This study canact as amodel to demonstrate theutility of theH-FABP
immunotest in the developing countries. In the second phase of this
study, we will conduct a cost-effectiveness analysis on the utility of this
test in the routine clinical practice and investigate whether this test
can improve the clinical outcome and shorten the time of diagnosis
compared to the original protocol.
The potential of this rapid and sensitive H-FABP immunotest in the
detection of myocardial infarction is considerable. It may help
physicians to diagnose AMI more accurately and earlier, leading to
improved treatment that will reduce patient morbidity and mortality
and prevent unnecessary hospital stays for non-AMI patients. This
sophisticated and effective diagnostic tool could enable both
physicians and patients to control diseases that now cause extensive
disability and loss of life worldwide.Acknowledgement
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